Implication of BRCA1/2 germline variants for childhood AML biology and treatment.
Professor Richard D’Andrea
University of South Australia
We have uncovered a novel mechanism associated with development of childhood AML, an aggressive childhood malignancy. Our studies suggest that a significant percentage of childhood AML patients will benefit from tailored therapy with approved clinical agents. To test this we propose a number of experiments using AML patient samples.